Get started
Author

Stéphane Jacquot

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab
2019 · Anthony Dohan, Benoit Gallix, et al. · Gut · 138
Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers’ experience
2002 · Bruno Cutuli, Christine Cohen-Solal-le Nir, et al. · International Journal of Radiation Oncology*Biology*Physics · 126
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)
2018 · Thomas Aparicio, Francois Ghiringhelli, et al. · Journal of Clinical Oncology · 96
PDF
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials
2018 · Thomas Aparicio, Michel Ducreux, et al. · European Journal of Cancer · 46
PDF
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
2023 · Valérie Boige, Hélène Blons, et al. · JAMA Network Open · 28
PDF
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
2017 · B. Besse, J. Mazières, et al. · Annals of Oncology · 24
PDF
Breast Cancer: How Hippotherapy Bridges the Gap between Healing and Recovery—A Randomized Controlled Clinical Trial
2023 · Hélène Viruega, Corinne Galy, et al. · Cancers · 15
PDF
Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ
2021 · Celine Bourgier, Didier Cowen, et al. · Radiotherapy and Oncology · 9
PDF
Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.
2016 · Thomas Aparicio, Jaafar Bennouna, et al. · Journal of Clinical Oncology · 8
Maintaining professional activity during breast cancer treatment
2016 · G. Ganem, E.-C. Antoine, et al. · European Journal of Cancer Care · 8
PDF
Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial
2026 · Cécile Ortholan, Anne Aupérin, et al. · The Lancet Healthy Longevity · 6
PDF
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
2022 · Bernadette de Rauglaudre, Camille Sibertin-Blanc, et al. · Therapeutic Advances in Medical Oncology · 5
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer
2026 · Emmanuelle Samalin, Hélène Senellart, et al. · The Oncologist · 3
Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial
2025 · Celine Bourgier, Caroline Mollevi, et al. · International Journal of Radiation Oncology*Biology*Physics · 3
Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.
2016 · Camille Sibertin-Blanc, Aurelie Fabre, et al. · Journal of Clinical Oncology · 3
Interim Analysis of Prodige 9, a Randomized Phase III Trial Comparing No Treatment to Bevacizumab Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer
2014 · T. Aparicio, J. Bennouna, et al. · Annals of Oncology · 2
Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment
2026 · Valérie Boige, Olivier Bouché, et al. · Clinical Cancer Research · 1
Evaluation of physical rehabilitation in patients receiving curative treatment for head and neck cancer: The NUTRIMOUV randomized phase II trial
2025 · Marie Vinches, Chloé Janiszewski, et al. · Supportive Care in Cancer · 1
PDF
OC-0594 Acute toxicity results after breast-conserving therapy in “boost vs no boost (BONBIS)” DCIS trial
2019 · C. Bourgier, D. Cowen, et al. · Radiotherapy and Oncology · 1
PDF
Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)
2017 · E. Samalin, H. Senellart, et al. · Annals of Oncology · 1
Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA).
2017 · Anthony Dohan, Benoit Gallix, et al. · Journal of Clinical Oncology · 1
Continuing to work while receiving cancer treatment: A financial or a symbolic issue?
2013 · Gerard Ganem, Herve L. Naman, et al. · Journal of Clinical Oncology · 1
Maux et espoirs de la fonction publique Arnaud Bontemps , Service public ou barbarie , La Découverte, « Petits cahiers libres », 2026, 336 pages, 17,50 €. Christelle Mazza , Souffrance au travail dans le service public. Sortir du silence. Entrer en résistance , préface de Christophe Dejours, Puits fleuri, 2026, 720 pages, 29 €.
2026 · Stéphane Jacquot · Études
Faouzia Farida Charfi Lettre à mon petit-fils sur l’islam d’aujourd’hui Odile Jacob, 2026, 216 pages, 19,90 €.
2026 · Stéphane Jacquot · Études
Supplementary Data 2 from Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment
2026 · Valérie Boige, Olivier Bouché, et al.
Works count: 40
Citation count: 526
H-index: 8
I10-index: 7
Year
Topic
Type